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Abstract 
The first generation bioresorbable scaffolds (BRS) did not 
deliver their promise for reduced risk of late stent thrombosis and 
neoatherosclerosis forming inside the stent and restoration of 
endothelial vasomotion. To our chagrin, the incidence of early, 
late and very late scaffold thrombosis was higher than 
conventional metallic stents leading to increased rates of adverse 
cardiovascular events and outcomes. Unfortunately, it took a 
decade to fully appreciate these major drawbacks. The 
manufacturer of the first, apparently hastily approved BRS in 
both Europe and the USA discontinued its production in 
September 2017. Nevertheless, hope remains and newer 
generation BRS are already in the pipeline expecting that 
improved technology and implantation strategies may overcome 
these severe limitations and finally recredit and reinstate the 
BRS concept. Rhythmos 2018;13(2): 26-29.   
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Abbreviations: BRS = bioresorbable scaffold; BVS = bioresorbable 
vascular scaffold; EES = everolimus eluting stent; MI = myocardial 
infarction; RR = relative risk   
Introduction  
Despite more complications, including early and late 
thrombosis, reported with the first available drug-eluting 
bioresorbable scaffold / stent (BRS),1, 2 the Absorb 
bioresorbable vascular scaffold (BVS) (Abbott Vascular, 
Santa Clara, CA, USA), an everolimus-eluting BRS, this 
stent received CE Mark approval in Europe in 2011 
(www.medscape.com/viewarticle/735561) and was 
approved by the US Food and Drug Administration (FDA) 
in July 2016 (www.fda.gov/NewsEvents/Newsroom/Press 
Announcements/ucm509805.htm). Unlike metallic stents, 
bare or drug-eluting, the BRS is gradually absorbed in the 
body over 2-5 years. The undelivered promise of the BRS 
was the potential for reduced risk of late stent thrombosis 
and neoatherosclerosis forming inside the stent and 
restoration of endothelial vasomotion.   
ABSORB Trials  
The first human implants of the Absorb BVS took 
place in 2006.3 After the publication of proof of concept 
and imaging studies, and early favorable reports in small 
number of patients,4-6 the disappointing results of the 
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ABSORB II randomized controlled trial (RCT) in 501 
patients were published in 2016.7 The trial did not meet its 
endpoints of superior vasomotor reactivity and non-
inferior late luminal loss for the Absorb BVS compared to 
the metallic stent, as there was no difference in vasomotor 
reactivity, while the BVS had significantly higher late 
luminal loss. In addition, a higher rate of target vessel 
myocardial infarction (MI), including peri-procedural MI, 
was observed in the Absorb group.  
Furthermore, there followed the results of the 
ABSORB III trial which were also worrisome. The trial 
demonstrated noninferior rates of target lesion failure 
(cardiac death, target vessel MI, or ischemia-driven target 
lesion revascularization) at 1 year in 2,008 patients with 
coronary artery disease randomized to BVS versus cobalt-
chromium everolimus-eluting stents (EES).8  Through 3 
years, the primary composite endpoint of target lesion 
failure occurred in 13.4% of BVS patients and 10.4% of 
EES patients (p = 0.06), and between 1 and 3 years in 7% 
vs 6% of patients, respectively (p=0.39). However, target 
vessel MI through 3 years was increased with BVS (8.6% 
vs. 5.9%; p=0.03), as was device thrombosis (2.3% vs. 
0.7%; p=0.01). In BVS-assigned patients, treatment of 
very small vessels (<2.25 mm) was an independent 
predictor of 3-year target lesion failure and scaffold 
thrombosis.   
BRS Thrombosis  
The most worrisome of all problems associated with 
the first generation of BRS relates to their long-term safety 
with regards to increased risk of thrombosis;1, 2 a recent 
RCT (AIDA) comprising 1845 patients receiving either a 
BRS (924 patients) or a metallic stent (921 patients), 
target-vessel failure was similar in the two groups (11.7% 
vs 10.7%, respectively; hazard ratio-HR, 1.12), however, 
device thrombosis was higher in the BRS group (2-year 
cumulative event rates, 3.5% vs. 0.9%; HR, 3.87; P<0.001) 
through 2 years of follow-up. 9  
A network meta-analysis including 91 trials confirmed 
that the Absorb BVS was associated with increased risk of 
long-term and very late scaffold thrombosis compared to 
current-generation metallic drug-eluting stents.10  Another 
meta-analysis of 7 trials in which 5583 patients were 
randomly assigned to Absorb BVS (n=3261) or metallic 
EES (n=2322) and followed up for 2 years showed that the 
BVS had higher 2-year relative risks of the device-oriented 
composite endpoint than did EES (9.4% vs 7.4%; relative 
risk -RR 1.29, p=0ꞏ0059).11 These differences were driven 
by increased rates of target vessel-related MI (5.8% vs 
3.2%; RR 1.68, p=0ꞏ0003) and ischemia-driven target 
lesion revascularization (5.3% vs 3.9%; 1.40, p=0.0090) 
with BVS, with non-significant differences in cardiac 
mortality. The cumulative 2-year incidence of device 
thrombosis was higher with BRS than with EES (2.3% vs 
0.7%; RR 3.35, p<0ꞏ0001). The authors concluded that 
BRS was associated with increased rates of adverse events 
and device thrombosis cumulatively at 2 years and 
between 1 and 2 years of follow-up compared with EES. 
Very similar results were reported by another review of 
these 7 trials including 5,583 patients randomized to 
receive either the study BVS (n = 3,261) or the EES (n = 
2,322). 12 Over a median of 2 years, risk of target lesion 
failure (9.6% vs. 7.2%, p = 0.003) and stent thrombosis 
(2.4% vs. 0.7%, p< 0.0001) were both significantly higher 
with BRS.   
Mechanisms and Risk Factors for BRS Thrombosis  
When the results of all the major ABSORB trials were 
analyzed, it was indicated that vessel sizing and operator 
technique were strongly associated with BVS-related 
outcomes during 3-year follow-up; the optimal approach 
that was recommended comprised the concept of the so-
called “PSP” (optimal predilation, vessel and device 
sizing, and post-dilation) to optimize BVS outcomes.13  
Thus, incomplete strut apposition appears to be the most 
important reason for BRS thrombosis with a detrimental 
outcome; improving the implantation technique may be 
able to overcome this horrendous BRS complication.14 
Furthermore, some studies have indicated that patient 
characteristics (e.g. ST-elevation MI, small vessel-
diameter, etc.) may adversely impact BRS thrombosis.15  
Other studies have proposed BRS design with scaffold 
discontinuity suggesting an unfavorable resorption-related 
process as the most common mechanism underlying very 
late BRS thrombosis, (42%), followed by strut 
malapposition (18%) and neoatherosclerosis (18%).16  
Finally, recommendations from an Expert Panel are 
provided for the optimal approach to use of the current 
generation BRS to minimize complications and risks 
associated with this early technology, including longer (2- 
to 3-year) duration of dual antiplatelet therapy if the 
bleeding risk is low.17   
Due to all these dismal results with the first-generation 
BRS, Abbott stopped selling and discontinued the 
production of the Absorb BVS in September 2017 
(www.vascular.abbott/us/products/coronary-intervention/ 
absorb-bioresorbable-scaffold-dissolving-stent.html), while 
Boston Scientific scrapped the development of their BRS 
(https://www.massdevice.com/boston-scientific-end-renuvia-
bioresorbable-coronary-stent-program/).    
Newer Generation BRS  
Although all these results have been disappointing and 
a setback for this novel technology, newer generation BRS 
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with improved technologies are being developed (Table 1) 
and tested in newer trials.18-20 Whether these newer BRS 
may overcome the limitations of the first generation BRS 
remains to be seen in future RCTs. Recently, one such trial 
tested NeoVas, a new poly-l-lactic acid BRS that elutes 
sirolimus from a poly-D, l-lactide coating, in 560 patients 
randomized to NeoVas BRS (n=278) and cobalt-
chromium everolimus-eluting stents (CoCr-EES) 
(n=282).21 It showed that the NeoVas BRS was noninferior 
to CoCr-EES for the primary endpoint of 1-year 
angiographic in-segment late loss, and resulted in 
comparable 1-year clinical outcomes, including recurrent 
angina. However, the ABSORB trials had similarly 
favorable results initially, and it was only after longer-term 
follow up that all turned sour and dreaded adverse effects, 
particularly late thrombosis, became apparent. 
Nevertheless, the dream of a “vanishing stent” remains 
alive in an attempt to restore vasomotion and achieve 
regression of underlying plaque, and vessel remodelling 
leading to an increased vessel lumen size. Only time will 
tell whether this technology will remain a dream or 
become a reality. A recent study from the Massachusetts 
Institute of Technology identified structural irregularities 
and asymmetric material degradation as the main design 
flaw in the first-generation BRS, generating hope for 
future technological improvements in this field.22    
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Table 1. Bioresorbable Vascular Scaffolds / Bioresorbable Stents 
 
BRS Model Manufacturer Scaffold / Eluted drug Strut / Coat 
thickness 
Full 
absorption 
CE 
mark 
FDA 
approval 
ABSORB BVS Abbott * PLLA / everolimus  150 / 3 μm ~3 years 1/2011 7/2016 
DESolve CX Elixir Medical PLLA / novolimus 120/<3 μm ~1 year 5/2014 - 
ART PURE ART & Terumo PDLLA / sirolimus 170 / - μm ~1 year 5/2015 - 
MAGMARIS Biotronik Mg / sirolimus 150/8 μm ~1 year 6/2016 - 
FANTOM Reva Medical TP / sirolimus 125 / - μm ~1 year 4/2017 - 
NeoVas Lepu Medical PLLA / sirolimus 180 μm NA - - 
MAGNITUDE Amaranth Medical PLLA / sirolimus 98 /- μm ~ 1 year - - 
IDEAL 
BIOSTENT 
Xenogenics poly-anhydride ester (SA 
& AAA) / sirolimus +SA 
175 μm ~ 1 year - - 
MIRAGE Manli Cardiology Ltd PLLA / sirolimus 170 μm ~ 1 year - - 
Xinsorb Huaan Biotechnology PLLA / sirolimus 160 μm 2-3 years - - 
MeRes100 Meril R&D PLLA / sirolimus 100 μm 2-3 years - - 
Firesorb MicroPort PLLA/ sirolimus 100-125 μm ~ 1 year - - 
Unity QualiMed Mg+PLLA/ sirolimus 160 μm ~ 1 year - - 
On-ABS OrbusNeich Medical PLLA/EPC+sirolimus 150 /- μm NA - - 
 
AAA = adipic acid anhydride; BRS = bioresorbable scaffolds; EPC = endothelial progenitor cell (capture technology); Mg = magnesium; 
PDLLA = poly-d,l-lactic acid; PLLA = poly-l-lactic acid; SA = salicylic acid; TP = tyrosine polycarbonate  
 
* discontinued production in September 2017 
 
   
